The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2
Background: Psoriatic arthritis (PsA) is a chronic inflammatory condition predominantly affecting the peripheral joints. However, some patients with PsA can experience axial involvement which is manifested with back pain and associated with increased burden of illness. Objectives: The aim of this po...
Main Authors: | Atul Deodhar, Dafna Gladman, Rebecca Bolce, David Sandoval, So Young Park, Soyi Liu Leage, Peter Nash, Denis Poddubnyy |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-08-01
|
Series: | Therapeutic Advances in Musculoskeletal Disease |
Online Access: | https://doi.org/10.1177/1759720X231189005 |
Similar Items
-
Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
by: Coates, L, et al.
Published: (2022) -
Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
by: Coates, LC, et al.
Published: (2022) -
Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials
by: Coates, L, et al.
Published: (2018) -
Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
by: Maxime Dougados, et al.
Published: (2022-12-01) -
Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1)
by: Hideto Kameda, et al.
Published: (2023-10-01)